Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.
Clinical Trials
1
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Recruiting
1
100.0%
No approval data available
- Award-winning NIH-funded research demonstrates that Aclarion's Nociscan magnetic resonance spectroscopy technology can identify immune-associated biological signatures in chronic low back pain patients. - The study used Nociscan's MRS methodology to measure intradiscal propionic acid levels, revealing distinct systemic immune activation patterns in patients with Modic type 1 changes. - Findings suggest potential expansion of Nociscan's clinical applications beyond surgical decision support to include personalized treatment strategies based on biological pain mechanisms. - Research indicates that elevated propionic acid levels can identify patient subgroups with specific immune system activation, particularly involving B-cells that produce antibodies.
- Northwestern Medicine and Scripps Health have enrolled their first patients in Aclarion's pivotal CLARITY trial, bringing the total number of active enrollment sites to four out of seven approved centers. - The multi-site trial aims to evaluate whether Nociscan technology can improve surgical outcomes beyond the current 54% industry benchmark for chronic low back pain surgery patients. - The company targets enrolling 25% of the planned 300 patients by Q2 2026, with initial interim data readout expected in Q3 2026 after the first cohort completes 3-month follow-up visits.
- UHealth-University of Miami Health System has enrolled the first two patients in Aclarion's pivotal CLARITY trial, testing Nociscan technology for chronic low back pain surgical outcomes. - The randomized 300-patient study evaluates whether Nociscan's MR spectroscopy and AI algorithms can improve spine surgery results by identifying painful disc sources. - The multi-center trial includes major medical institutions and aims to demonstrate clinical and economic value, with interim results expected in Q2 2026.
- Keck Medical Center of USC has joined the CLARITY trial to evaluate Aclarion's Nociscan technology, which uses MR Spectroscopy and AI to identify sources of chronic low back pain. - The randomized, multi-center CLARITY trial will enroll 300 patients across prestigious institutions including Johns Hopkins Medicine, Northwestern Medicine, and Texas Back Institute. - Nociscan is the first evidence-supported platform to noninvasively distinguish between painful and nonpainful discs in the lumbar spine, potentially transforming diagnosis and treatment for 266 million people worldwide with degenerative spine disease.
- Northwestern Medicine, a leading clinical research institution that conducted over 6,900 studies in 2024, has been selected as the initial site for Aclarion's CLARITY trial investigating Nociscan technology. - The CLARITY trial, a fully-funded randomized study of 300 patients, aims to evaluate Nociscan's effectiveness in improving surgical outcomes for chronic low back pain through MR Spectroscopy and AI technology. - Led by Dr. Nicholas Theodore of Johns Hopkins, the study will compare surgical outcomes between physicians with and without access to Nociscan's biomarker data for treating discogenic low back pain.
- Aclarion's CLUE trial, evaluating Nociscan's impact on chronic low back pain treatment, expands to New Jersey with Dr. Justin Kubeck joining the study. - The CLUE trial aims to gather real-world evidence on how Nociscan's AI-driven data influences treatment decisions for patients with chronic low back pain. - Nociscan is a SaaS platform that analyzes chemical biomarkers to distinguish between painful and nonpainful discs, aiding physicians in optimizing treatment strategies. - Aclarion seeks to demonstrate Nociscan's clinical utility to payers, potentially driving early coverage decisions for the diagnostic tool.
